wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q35748507-096343FE-950A-4FDB-BB8A-74788C39EC12
Q35748507-096343FE-950A-4FDB-BB8A-74788C39EC12
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35748507-096343FE-950A-4FDB-BB8A-74788C39EC12
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study
P2860
Q35748507-096343FE-950A-4FDB-BB8A-74788C39EC12
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35748507-096343FE-950A-4FDB-BB8A-74788C39EC12
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
90268ee80c186ad2a8f0347c486d06d719360e9b
P2860
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.